How Axsome Therapeutics Crossed a Billion-Dollar Revenue Run Rate in Q3 2026(NASDAQ:AXSM)

Sonal Goyal

03 November 2026 07:02 PM AEDT

How Axsome Therapeutics Crossed a Billion-Dollar Revenue Run Rate in Q3 2026(NASDAQ:AXSM)

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Revenue Milestone: Total Q3 2026 net product Revenue reached $259.7 million, a 52% increase over the same period in 2025, placing the company above a billion-dollar annualized pace.
AUVELITY Growth: The flagship antidepressant generated $207.6 million in net product sales, up 53% year-over-year, with prescriptions rising 40% and new patient starts increasing 44%.
Narrowing Net Loss: The net loss for Q3 2026 was $12.9 million, or $0.25 per share, compared with a loss of $47.2 million, or $0.94 per share, in Q3 2025.
Pipeline Expansion: The SUMMIT Phase 3 trial of AXS-05 for smoking cessation was initiated in August 2026, adding to a pipeline targeting multiple CNS indications.

Axsome Therapeutics, Inc.(NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system disorders, reported third quarter 2026 financial results that show accelerating commercial momentum across its product portfolio. Total net product revenue of $259.7 million for the quarter exceeded the threshold that places the company's annual revenue run rate above one billion dollars for the first time.

AUVELITY Drives Revenue and Alzheimer's Expansion

AUVELITY, Axsome's oral NMDA receptor antagonist and sigma-1 receptor agonist, is approved in the US for major depressive disorder in adults and for agitation associated with dementia caused by Alzheimer's disease. Net product sales of $207.6 million in Q3 2026 represented a 53% year-over-year increase and a 14% sequential gain from the prior quarter. Approximately 302,000 total prescriptions were written for the drug during the quarter, up 40% from Q3 2025, with new-to-brand prescriptions rising 44% year-over-year and 21% quarter-over-quarter.

The Alzheimer's agitation indication, which received US approval in 2024, appears to be gaining traction with older patient populations. Third quarter prescriptions for patients aged 65 and older increased by more than 200% year-over-year for new starts and more than 100% for total prescriptions. Payer coverage for AUVELITY currently sits at approximately 89% of insured lives, with government programs including Medicare and Medicaid at 100% coverage. CEO Herriot Tabuteau said in a prepared statement that new patient initiations in Alzheimer's agitation are continuing to accelerate.

SUNOSI and SYMBRAVO Add to the Revenue Base

SUNOSI, a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness in patients with obstructive sleep apnea or narcolepsy, contributed $48.2 million in net product revenue for the quarter — a 47% year-over-year increase that included net product sales of $38.5 million, royalties from out-licensed territories of $1.2 million, and $8.5 million in milestone revenue. Approximately 64,400 prescriptions were filled in the US during Q3 2026, a 15% gain over the same quarter last year.

SYMBRAVO, approved for the acute treatment of migraine, generated $3.9 million in net product sales — 88% more than Q3 2025 — with approximately 25,000 prescriptions written during the quarter. Payer coverage for SYMBRAVO remains below that of the other two products at roughly 57% of insured lives, which the company is likely to address through ongoing payer contracting work.

Risks

Selling, general, and administrative expenses reached $203.1 million in Q3 2026, up from $150.2 million in Q3 2025, reflecting the cost of commercializing AUVELITY and SYMBRAVO. Research and Development spending came to $50.6 million, driven by ongoing trials for solriamfetol and AXS-05. The company carries a net loss despite meaningful revenue growth, and achieving Cash Flow positivity will depend on how quickly revenue continues to outpace operating costs. Payer coverage for SYMBRAVO at 57% remains a limiting Factor for that product's near-term growth.

What to Watch Next

Axsome has disclosed multiple clinical milestones expected within the next 12 to 18 months. Topline results from the SUMMIT Phase 3 smoking cessation trial and the ENGAGE binge eating disorder study are anticipated in 2027. The FOCUS-2 and FOCUS-3 trials of solriamfetol for ADHD in children and adolescents should also report topline data in the second half of 2027. The company stated it believes current cash — $313.9 million at September 30, 2026 — is sufficient to fund operations through cash flow positivity based on the current plan.

Sector Context

The CNS drug market has historically been characterized by high development attrition and limited commercial successes, but a wave of approvals in depression, Alzheimer's, and sleep medicine over the past several years has changed perceptions about the category. AUVELITY's combination mechanism — NMDA antagonism and sigma-1 receptor agonism — is distinct from the majority of established antidepressants, and the Alzheimer's agitation indication opens access to a patient population that has few approved pharmacological options. The company's ability to scale commercially while running a multi-product pipeline simultaneously will continue to attract scrutiny from industry observers.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.